Who is sponsoring NCT04601350?

NCT04601350 is sponsored by Yangzhou University.

What condition does NCT04601350 study?

NCT04601350 studies Benzodiazepine.

Is NCT04601350 still recruiting?

NCT04601350 is currently completed. Last updated 16 January 2024.

Last reviewed 2024-01-16 · How we verify

NCT04601350

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Remimazolam Use During Perioperative Period on Brain Waves and Postoperative Cognitive Function

Completed NA Last updated 16 January 2024

What this trial tests

NA trial testing remimazolam group was induced with remimazolam 0.1 mg/kg followed by a maintenance dose of 0.1 mg·kg-1·h-1 for general anesthesia in Benzodiazepine in 80 participants. Completed in 1 June 2022.

Timeline

1 November 2020

Primary endpoint
1 May 2022

1 June 2022

Quick facts

Lead sponsor	Yangzhou University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	prevention
Enrollment	80
Start date	1 November 2020
Primary completion	1 May 2022
Estimated completion	1 June 2022
Sites	1 location across China

Drugs / interventions tested

remimazolam group was induced with remimazolam 0.1 mg/kg followed by a maintenance dose of 0.1 mg·kg-1·h-1 for general anesthesia
control group was induced with midazolam 0.05 mg/kg followed by normal saline maintenance of 0.1 ml·kg-1·h-1

Conditions studied

Benzodiazepine — all drugs for Benzodiazepine →

Sponsor

Yangzhou University

Who can join

Eligibility, any sex, with Benzodiazepine. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Benzodiazepine sedative hypnotics are commonly used intravenous anesthetics in clinical practice. Remimazolam is a new benzodiazepine with the characteristics of rapid onset, short maintenance and recovery time, no accumulation, metabolism independent of liver and kidney function, and no serious side effects, which has a good prospect for clinical application. Now we will study the effects of remimazolam on EEG and postoperative cognitive function ，in order to further understand the clinical application of remimazolam.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Remimazolam: pharmacological characteristics and clinical applications in anesthesiology.
Kim KM. · · 2022 · cited 161× · PMID 35139608 · DOI 10.17085/apm.21115
Effective and safe pediatric sedation.
Jang YE, Kim JT. · · 2024 · cited 4× · PMID 39069650 · DOI 10.17085/apm.24046
Effects of Remimazolam on Intraoperative Frontal Alpha Band Power Spectrum Density and Postoperative Cognitive Function in Older Adults Undergoing Lower Extremity Fractures Surgeries: A Randomized Controlled Trial.
Wu H, Tian S, Ma H, Zhou W, et al · · 2024 · cited 3× · PMID 39764357 · DOI 10.2147/cia.s496437

Verify or expand the search:

Other Yangzhou University trials

Trials by the same sponsor.

NCT06517069 — Effect of TEAS Combined With Oxycodone on Postoperative Visceral Pain in Gynecologic Laparoscopic Patients · NA · recruiting
NCT05936918 — Application of Transcutaneous Electrical Acupoint Stimulation in Laparoscopic Cholecystectomy · NA · unknown
NCT05909696 — Median Effective Dose of Rocuronium for the Prevention of Myofibrillation Caused by the Injection of Succinylcholine · NA · completed
NCT05932485 — Effect of Stellate Ganglion Block on New Atrial Fibrillation After Coronary Artery Bypass Grafting · NA · completed
NCT06456710 — Effect of a Psychological Intervention on Stigma: a Randomized Controlled Study · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04601350 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yangzhou University
Last refreshed: 16 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04601350.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing